Novel Cell-Based Assays to Accelerate Cancer Immunotherapies. Abhi Saharia, Ph. D. Director, Cell-Based Assays

Transcription

1 Novel Cell-Based Assays to Accelerate Cancer Immunotherapies Abhi Saharia, Ph. D. Director, Cell-Based Assays 1

2 ionc drugs Powerful Cancer Treatments Clinical success of Checkpoint mabs from Merck & BMS Bi-specifics from Amgen ADCC-based drugs (Rituximab etc.) CAR-T therapy James Allison 2

3 The Cancer-Immunity Cycle & Targeted Therapies PD-1: Pembrolizumab Nivolumab Pidilizumab PD-L1: MPDL3280A BMS MEDI4736 CTLA4: Ipilimumab Tremelimumab LAG3: IMP321 OX40 CD137 CD40 3 Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 39 (1). Pgs 1-10 The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, 2012.

4 A quick introduction to DiscoverX Privately held company, founded in 2001 Global presence in 30+ countries with 140 employees Deep assay development expertise Extensive relationship with 1000s of companies including every major pharma Industry s Most Comprehensive Portfolio Drug Discovery Assays and Screening Services 4

5 Agenda Checkpoint Receptor Assays PD-1 Assay with PD-L1 and PD-L2 CD40 Assay OX40 Assay VISTA Assay Immune-mediated Cytotoxicity Assays ADCC ADCP CAR-T T-Cell Redirecting Bi-specific Antibodies 5

6 Challenges with Checkpoint Receptors Difficult to create cell-based assays for checkpoint receptors Often need primary human cells Need for co-culture Difficult to handle human primary cells Highly variable Long, complicated protocols Assay not specific for target receptor 6

7 7 Enzyme Fragment Complementation (EFC)

8 8 PathHunter PD-1 Signaling Assay

9 9 Simple, Add and Read Protocol

10 10 Robust Assay with PD-L1 & PD-L2

11 11 PD-1 Assay Has a Highly Specific Response

12 12 PathHunter 15X More Sensitive vs. Reporter Gene Assay

13 13 Broad Applications for Small Molecules & Biologics

14 Summary For Checkpoint Assays No human blood cells needed for this biologically relevant response Simple protocol with rapid results in under 6 hours Highly sensitive >15-fold better sensitivity than existing assays Highly specific assay response to PD-L1 and PD-L2 and their inhibitors Broad Applications for small molecule & biologics screening as well as QC lot release assays Assay Name Ligand PD-1 Signaling Assay PD-L1 or PD-L2 PathHunter U2OS PD-L1 Ligand Cell Line - PathHunter U2OS PD-L2 Ligand Cell Line - PathHunter U2OS VISTA/VISTA Dimerization Cell Line Anti-VISTA Antibody PathHunter U2OS NIK Signaling Assay CD40, LIGHT or TWEAK PathHunter U2OS OX40 Signaling Assay OX40 14

15 Agenda Checkpoint Receptor Assays PD-1 Assay with PD-L1 and PD-L2 CD40 Assay OX40 Assay VISTA Assay Immune-mediated Cytotoxicity Assays ADCC ADCP CAR-T or T-Cell Therapies T-Cell Redirecting Bi-specific Antibodies 15

16 Challenge For Developing Cancer Immunotherapies How to determine target cell death specifically in the presence of multiple cell types in a well?? How to get sensitive detection of target cell death for ADCs? ADCC ADCP ADCs CAR-T Bispecific Ab 16

17 Challenges with Existing Cytotoxicity Assays Dye-based assays are radioactive and/or leaky General cell death measures are not specific for target cells Assays are complicated and long Low throughput of assays 17

18 18 Introducing the KILR Cytotoxicity Assay

19 Simple, Add and Read Protocol Comparison to Chromium51 Release Protocol 19

20 20 Unparalleled Sensitivity of KILR Assays

21 R L U Ultimate Flexibility Ability to run assay from 30 minutes to 72 hours K IL R M C F -7 C e lls Protein reporter stable for 72 hours in media Low background non-leaky protein reporter h r 4 8 h r 7 2h r T r ito n X [% ] EC50 24hr hr hr S /B

22 KILR Applications ADCC ADCP ADCs CAR-T Bispecific Ab 22

23 % ly s is R L U KILR Applications Antibody Dependent Cellular Cytotoxicity ADCC 4 0 ADCC Assay Verified with Marketed Drugs E rb B 2 O v e r-e x p re s s in g C e ll P o o ls 4 :1 N K : ta rg e t c e lls U 2 O S -E G F R e P L T ra s tu z u m a b [g /m L ] HillSlope EC50 S /B SKBR e MCF e NCI N e A n tib o d y [g /m L ] HillSlope EC50 S /B Cetuximab e Rituximab ~ ~ 5.119e

24 KILR Applications ADCC for QC Lot Release Assays IC50 (ng/ml) Relative Potency R 2 Ref. Std % Ctrl % % % % Key Benefits True MOA of ADCC molecule Accurate Precise Reproducible Robust 24 Data provided courtesy of Amgen

25 KILR Applications Antibody Dependent Cellular Phagocytosis ADCP with with Primary Macrophages 25 Data provided courtesy of Janssen

26 KILR Applications Bispecific Antibody for T-cell Redirection BiSpecific Ab Plate Target Cells in 384-well plate Add non-activated primary T cells Add antibody 41 hrs Add KILR Detection reagent 1h Read signal 26 Data provided courtesy of Janssen

27 Summary for KILR Cytotoxicity Assays Highly-specific measure of target cell death in co-culture Easy to use with simple add and read protocol Highly sensitive detection of as few as 75 dead cells in a well Broad applications for ionc drug development 27 Cell Lines KILR ARH-77 Cell Line KILR SKBR3 Cell Pool KILR H322 Cell Pool KILR NCI-N87 Cell Pool KILR Ramos Cell Pool KILR Raji Cell Pool KILR A549 Cell Pool KILR SKOV3 Cell Pool

28 Acknowledgements DiscoveRx Team Jane Lamerdin Hanako Daino-Laizure Jennifer Lin-Jones Mimi Nguyen Jason van der Tuig Sailaja Kuchibhatla 28

29 Questions To learn more, go to discoverx.com Posters with additional data located in poster session Poster #7 Poster #8 29